ST2 Levels Before and After Treatment of NYHA III and IV Heart Failure
Aim: to find whether ST2 can be used to determine clinical improvement in patients with NYHA III and IV heart failure. Methods: this is a longitudinal, pre and post-test study without a control group. Study subjects are 23 NYHA III and IV heart failure patients. ST2 was tested at the start and end o...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Interna Publishing
2015-12-01
|
Series: | Acta Medica Indonesiana |
Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/22 |
id |
doaj-a0f9d9bd491b4d4a897a2714657964e4 |
---|---|
record_format |
Article |
spelling |
doaj-a0f9d9bd491b4d4a897a2714657964e42020-11-24T22:42:45ZengInterna PublishingActa Medica Indonesiana0125-93262338-27322015-12-0147422ST2 Levels Before and After Treatment of NYHA III and IV Heart FailureSuzanna Immanuel0Neila Mona AG Mandey1Lukman H Makmun2Department of Clinical Pathology, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaDepartment of Clinical Pathology, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaDepartment of Internal Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, IndonesiaAim: to find whether ST2 can be used to determine clinical improvement in patients with NYHA III and IV heart failure. Methods: this is a longitudinal, pre and post-test study without a control group. Study subjects are 23 NYHA III and IV heart failure patients. ST2 was tested at the start and end of hospital treatment. Results: of 23 heart failure patients, 70% were classified as NYHA III while 30% were NYHA IV. There were more male subjects than females (51.4% vs. 48.6%). Median age for NYHA III heart failure patients was 52 years and mean age for NYHA IV heart failure patients was 58 years. Heart failure was mostly caused by coronary artery disease (52%). ST2 levels did not correlate with age, length of care, sex and cause of heart failure. ST2 levels in NYHA IV heart failure patients (58.82±37.36 ng/mL) tended to be higher than the one in NYHA III group (30.75 [14.4-84.5] ng/mL), but the difference was statistically not insignificant (p=0.89). ST2 levels at the start of treatment was significantly higher than at the end (31.4 [14-129.2] ng/mL vs. 18.4 [7.6-77.8] ng/mL), p=0.001. This shows that clinical improvement is associated with significant reduction of ST2 levels. Conclusion: ST2 can be used as a marker to determine clinical improvement in NYHA III and IV heart failure. Key words: ST2, heart failure, NYHA III and IVhttp://www.actamedindones.org/index.php/ijim/article/view/22 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Suzanna Immanuel Neila Mona AG Mandey Lukman H Makmun |
spellingShingle |
Suzanna Immanuel Neila Mona AG Mandey Lukman H Makmun ST2 Levels Before and After Treatment of NYHA III and IV Heart Failure Acta Medica Indonesiana |
author_facet |
Suzanna Immanuel Neila Mona AG Mandey Lukman H Makmun |
author_sort |
Suzanna Immanuel |
title |
ST2 Levels Before and After Treatment of NYHA III and IV Heart Failure |
title_short |
ST2 Levels Before and After Treatment of NYHA III and IV Heart Failure |
title_full |
ST2 Levels Before and After Treatment of NYHA III and IV Heart Failure |
title_fullStr |
ST2 Levels Before and After Treatment of NYHA III and IV Heart Failure |
title_full_unstemmed |
ST2 Levels Before and After Treatment of NYHA III and IV Heart Failure |
title_sort |
st2 levels before and after treatment of nyha iii and iv heart failure |
publisher |
Interna Publishing |
series |
Acta Medica Indonesiana |
issn |
0125-9326 2338-2732 |
publishDate |
2015-12-01 |
description |
Aim: to find whether ST2 can be used to determine clinical improvement in patients with NYHA III and IV heart failure. Methods: this is a longitudinal, pre and post-test study without a control group. Study subjects are 23 NYHA III and IV heart failure patients. ST2 was tested at the start and end of hospital treatment. Results: of 23 heart failure patients, 70% were classified as NYHA III while 30% were NYHA IV. There were more male subjects than females (51.4% vs. 48.6%). Median age for NYHA III heart failure patients was 52 years and mean age for NYHA IV heart failure patients was 58 years. Heart failure was mostly caused by coronary artery disease (52%). ST2 levels did not correlate with age, length of care, sex and cause of heart failure. ST2 levels in NYHA IV heart failure patients (58.82±37.36 ng/mL) tended to be higher than the one in NYHA III group (30.75 [14.4-84.5] ng/mL), but the difference was statistically not insignificant (p=0.89). ST2 levels at the start of treatment was significantly higher than at the end (31.4 [14-129.2] ng/mL vs. 18.4 [7.6-77.8] ng/mL), p=0.001. This shows that clinical improvement is associated with significant reduction of ST2 levels. Conclusion: ST2 can be used as a marker to determine clinical improvement in NYHA III and IV heart failure.
Key words: ST2, heart failure, NYHA III and IV |
url |
http://www.actamedindones.org/index.php/ijim/article/view/22 |
work_keys_str_mv |
AT suzannaimmanuel st2levelsbeforeandaftertreatmentofnyhaiiiandivheartfailure AT neilamonaagmandey st2levelsbeforeandaftertreatmentofnyhaiiiandivheartfailure AT lukmanhmakmun st2levelsbeforeandaftertreatmentofnyhaiiiandivheartfailure |
_version_ |
1725698559523684352 |